Creso Pharma Ltd (ASX: CPH) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Creso Pharma Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $54.51 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.40 billion
Earnings per share -0.027
Dividend per share N/A
Year To Date Return -52.44%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Creso Pharma Ltd (ASX: CPH)
Latest News

A white cannabis leaf set against a green background with a graph going up, indicating a rising share price for ASX cannabis shares
Cannabis Shares

What’s the outlook for ASX Cannabis shares in 2022?

December has been a tricky month for ASX cannabis shares.

Read more »

Back view of a man lifting hish hands high in front of hemp plants grown for cannabis.
Healthcare Shares

Here’s why the Creso Pharma (ASX:CPH) share price is surging 6% today

The cannabis and psychedelics company released a positive update today.

Read more »

A dollar sign embedded in ice, indicating a share price freeze or trading halt
Healthcare Shares

Why is the Creso Pharma (ASX:CPH) share price frozen today?

Creso is once again in a trading halt...

Read more »

a person holds their head in their hands as they slump forward over a laptop computer which features a thick red downward arrow zigzagging downwards across the screen.
Share Fallers

Why Creso Pharma, Hansen, Life360, and Serko shares are falling

These ASX shares are out of form on Thursday...

Read more »

Falling cannabis asx share price represented by cannabis leaves on a declining line graph
Healthcare Shares

Creso Pharma (ASX:CPH) share price down 7% as chair stands aside amid ASIC probe

The share price of the cannabinoid company is in the red.

Read more »

Scared, wide-eyed man in pink t-shirt with hands covering mouth
Share Fallers

Why the Creso Pharma (ASX:CPH) share price is down 29% this week

It has been another difficult day for the Creso Pharma Ltd (ASX: CPH) share price on Thursday. In early afternoon…

Read more »

A guys points his fingers down.
Cannabis Shares

Creso Pharma (ASX:CPH) share price down 6% after speeding ticket

Investors are keeping the Creso Pharma share price under heat following its response to the ASX yesterday.

Read more »

A dollar sign embedded in ice, indicating a share price freeze or trading halt
Healthcare Shares

Why the Creso Pharma (ASX:CPH) share price fell 9% before freezing

Creso Pharma shares came to a halt this afternoon, here's what is happening...

Read more »

CPH ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Creso Pharma Ltd

Creso Pharma Ltd is engaged in developing, registering, and commercialization of pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health. Its product portfolio includes Creso Animal Health products, Nutraceutical products, Topical products, Therapeutics products, and Lifestyle products. The company has operations in Switzerland, Canada, Colombia, Israel, and Australia. The company derives prime revenue from the Europe and Middle East regions.

CPH Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
12 Aug 2022 $0.04 $0.00 0.00% 4,296,227 $0.04 $0.04 $0.04
11 Aug 2022 $0.04 $0.00 0.00% 2,125,437 $0.04 $0.04 $0.04
10 Aug 2022 $0.04 $0.00 0.00% 2,744,918 $0.04 $0.04 $0.04
09 Aug 2022 $0.04 $0.00 0.00% 9,090,335 $0.04 $0.04 $0.04
08 Aug 2022 $0.04 $0.00 0.00% 9,999,262 $0.04 $0.04 $0.04
05 Aug 2022 $0.04 $0.00 0.00% 16,003,840 $0.04 $0.04 $0.04
04 Aug 2022 $0.04 $-0.01 -20.41% 8,650,575 $0.04 $0.04 $0.04
26 Jul 2022 $0.05 $0.00 0.00% 1,919,922 $0.05 $0.05 $0.05
25 Jul 2022 $0.05 $0.00 0.00% 3,318,227 $0.05 $0.05 $0.05
22 Jul 2022 $0.05 $0.00 0.00% 4,288,369 $0.05 $0.05 $0.05
21 Jul 2022 $0.05 $0.00 0.00% 7,223,093 $0.05 $0.05 $0.05
20 Jul 2022 $0.05 $0.00 0.00% 1,793,501 $0.05 $0.05 $0.05
19 Jul 2022 $0.05 $0.00 0.00% 2,252,845 $0.05 $0.05 $0.05
18 Jul 2022 $0.05 $0.00 0.00% 4,291,390 $0.05 $0.05 $0.04
15 Jul 2022 $0.04 $0.00 0.00% 2,601,325 $0.04 $0.05 $0.04

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
27 Jul 2022 Boaz Wachtel Expiry 1 $78,400
As advised by the company. Expiry of Performance Rights.
02 Nov 2021 Adam Blumenthal Issued 37 $4,925,502
Issue of options. As per announcement on 08/11/2021
02 Nov 2021 James Ellingford Issued 384 $49,941
Issue of options. As per announcement on 08/11/2021
02 Nov 2021 Boaz Wachtel Issued 2 $381,333
Issue of options. As per announcement on 08/11/2021.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Adam Blumenthal Non-Executive DirectorNon-Executive Chairman Nov 2015
Mr Blumenthal has over 11 years' experience in Investment Banking and Corporate Finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of unlisted and listed companies. Adam has played a lead role in advising and supporting multiple organisations across a broad spectrum of industries, using his experience and network of international contacts to provide corporate advisory and capital markets input. He has successfully brought to market several Medical Marijuana companies spanning Israel, Canada, Switzerland and Australia. He has also been actively involved in the Mining, Cyber Security, Health Care and IT sectors. He is a director of EverBlu Capital Pty Ltd, the Company's appointed corporate advisor and lead manager to the various capital raisings undertaken by the Company in CY2021. Outside of his formal business activities, Adam has lectured at a leading Sydney University covering corporate governance, corporate social responsibility and ASX listings - both at an undergraduate and postgraduate level. He is a supporter of Israeli innovation and has previously lived in Israel. He is a member of the Israel Business Club Sydney (IBCS).
Dr James Anthony Ellingford Executive Director Nov 2015
Dr Ellingford's professional life culminated in being President of an international publicly listed billion-dollar business with its headquarters in Geneva, Switzerland and New York, USA. He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.
Mr Boaz Wachtel Non-Executive Director Nov 2015
Mr Wachtel was Co-Founder and former Managing Director of MMJ-PhytoTech Ltd, Australia's first publicly traded Medical Cannabis Company. Co-founder of IMCPC - International Medical Cannabis Patient Coalition. He is an Israeli medical cannabis pioneer/activist, who formulated and assisted the Ministry of Health with the implementation of the National Medical Cannabis Program - one of only few national programs in the world. He is a frequent lecturer and adviser to governments, national committees, business and NGO's on medical cannabis program formulation, grow operations, international laws and UN drug convention compliance, as well as the founder (1999) and former Chairman of the Green Leaf Party, an Israeli political party for cannabis legalisation/medicalisation, human rights and ecology. Mr Wachtel is a certified clinical research manager and holds an MA in Management and Marketing from the University of Maryland.
Mr Bruce Andrew Linton Non-Executive Director Jan 2022
Mr Linton is a cannabis executive and has sector experience as a founder, CEO, Board member and advisor to a number of global cannabis and psychedelic focused companies. Mr Linton's experience include his role as founder, Chairman and ex-CEO of Canopy Group Corporation. Mr Linton was also responsible for securing market support for 16 funding rounds and progressing over 30 M&A opportunities. He led Canopy Growth through its start-up phase to becoming the first producing cannabis company to list on the New York Stock Exchange. Following his departure from Canopy Growth, he has led direct investments into the cannabis and psychedelic sector while undertaking management and strategic advisory roles. These include being Executive Chairman of Gage Cannabis Co. and a Director of psychedelic medicines company, Mind Medicines Inc.
Mr William Lay Chief Executive OfficerManaging Director Jan 2022
Mr Lay is an experienced cannabis executive and previously served as Executive Vice President - Strategy, Origination & Operations at Creso Pharma (refer ASX announcement: 6 September 2021). Mr Lay began his career with Canadian full service financial investment bank, BMO Capital Markets through roles across Canada and London. Shortly after his time with BMO Capital Markets, Mr Lay joined Canopy Growth Corporation (TSE: WEED, NASDAQ: CGC) as an M&A Associate, before being promoted to Associate Director, M&A, in 2019. In this role, he assessed and effected multiple transactions locally and internationally, while concurrently progressing corporate strategy initiatives across the group. Over the last four years, Mr Lay has managed and supported cannabis M&A transactions, including managing the acquisition in the history of the cannabis sector.
Mrs Micheline MacKay Executive Director Jan 2022
Mrs MacKay has 22 years of experience in regulatory environments, including pharmaceuticals, medical devices, and government regulated industries. She has held leadership positions for many years in different areas with a focus on business improvements and product development from laboratory scale to commercial operations. Mrs MacKay is currently the Corporate Manager of Creso Pharma's wholly owned Canadian subsidiary, Mernova Medicinal Inc. (Mernova). She has been in the position for nearly three years and is responsible for multiple functions including HR, quality assurance, and regulatory affairs. Mrs MacKay is the Health Canada designated Responsible Person in Charge at Mernova. She has practical experience in managing a business through specified key performance indicators, managing budgets, conducting regular audits and performance management.
Mr Winton William Willesee Joint Company Secretary Oct 2018
Ms Erlyn Dale Joint Company Secretary Oct 2018
Mr Chris Grundy Chief Financial Officer
Winton William Willesee Joint Company Secretary
Erlyn Dale Joint Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Atlantic Capital Holdings Pty <Atlantic Capital A/C> 100,415,432 8.18%
Jamber Investments Pty Ltd <The Amber Schwarz Fam A/C> 50,392,066 4.10%
Mr Tyson Scholz 35,524,240 2.89%
Mr Bill Fleming <Fleming Family 2011 A/C> 30,568,312 2.49%
Bnp Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 29,201,889 2.38%
Suburban Holdings Pty Ltd <The Suburban Super Fund A/C> 28,279,263 2.30%
Citicorp Nominees Pty Limited 19,440,848 1.58%
Hsbc Custody Nominees (Australia) Limited 15,551,767 1.27%
Atlantic Capital Holdings Pty Ltd <Atlantic Capital A/C> 13,250,000 1.08%
Brispot Nominees Pty Ltd <House Head Nominee A/C> 8,873,683 0.72%
International Water & Energy Savers Ltd 8,800,000 0.72%
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 6,972,451 0.57%
Mr John Langley Hancock 6,440,068 0.52%
Superhero Nominees Pty Ltd <Client A/C> 5,660,132 0.46%
Noble House Consulting Ltd 5,000,000 0.41%
Mr Kenneth Joseph Hall <Hall Park A/C> 5,000,000 0.41%
Mr Niall Buckley 4,680,256 0.38%
Mr Tyson Scholz I 4,500,000 0.37%
Mr Mitchel Fleming 4,399,440 0.36%
Mr Matthew Clarke Mallet 3,400,000 0.28%
Bnp Paribas Nominees Pty Ltd Acf Clearstream 3,031,955 0.25%